Getting your Trinity Audio player ready...
Abbott Laboratories stock declined 7.3 percent Tuesday after Charlene Lu, an analyst at Kidder, Peabody lowered her rating on the stock because of threats from makers of generic drugs. Lu lowered her rating on the North Chicago-based pharmaceutical company to “neutral” from “outperform” because Abbott’s Hytrin drug could face competition from generic versions. Hytrin is used to treat high blood pressure and benign prostate enlargement, Lu said. Abbott shares lost $2.12, to $26.87, on heavy volume.
